A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Matthews, MBBS, MCRP, PhD
ReCode Therapeutics, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centre Hospitalier Régional Universitaire de Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, France
- Hôpital Necker Enfants Malades
Paris, France
- Umc Utrecht
Utrecht, Netherlands
- New Zealand Clinical Research (part 1 Only)
Auckland, New Zealand
- University Hospitals Birmingham
Birmingham, United Kingdom
- Royal Papworth Hospital
Cambridge, United Kingdom
- Leeds Teaching Hospitals
Leeds, United Kingdom
- King'S College Hospital
London, United Kingdom
- Nottingham University Hospitals
Nottingham, United Kingdom
- University Hospital Southampton
Southampton, United Kingdom
- the University of Alabama at Birmingham
Birmingham, Alabama, United States
- University of Arizona
Tucson, Arizona, United States
- Stanford University
Palo Alto, California, United States
- Ucsd
San Diego, California, United States
- National Jewish Health
Denver, Colorado, United States
- Emory University
Atlanta, Georgia, United States
- Boston Children'S Hospital
Boston, Massachusetts, United States
- New York Medical College
Valhalla, New York, United States
- the University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Oregon Health & Science University
Portland, Oregon, United States
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
- Ut Southwestern Medical Center
Dallas, Texas, United States
- University of Washington
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Feb 2024
- Primary completion
- 30 Nov 2026
- Completion
- 30 Nov 2026
- Last update posted
- 19 Aug 2026
- Registered enrollment
- 128
- Registry id
- NCT06237335
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.